DJIA 16,528.03 -114.98 -0.69%
NASDAQ 4,776.51 -51.82 -1.07%
S&P 500 1,972.18 -16.69 -0.84%
market minute promo

Ophthotech (NASDAQ: OPHT)

44.03 -1.34 (-2.95%)

Quote as of


company name or ticker

Recent Quotes

OPHT $44.03 -2.95%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $45.34
Previous Close $45.37
Daily Range $43.96 - $46.51
52-Week Range $36.46 - $72.51
Market Cap $1.5B
P/E Ratio -45.83
Dividend (Yield) $0.00 (0.0%)
Volume 415,076
Average Daily Volume 468,233
Current FY EPS -$2.98

Sector

Industry

Ophthotech (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website: http://www.ophthotechinc.com/

News & Commentary

What's Behind Ophthotech's Rapid Run Higher in July?

A chance for its clinical-stage drug Fovista to become a go-to vision therapy is sending shares higher.

Commit To Purchase Ophthotech Corp At $50, Earn 29.2% Annualized Using Options

Will Ophthotech (OPHT) Continue to Surge Higher? - Tale of the Tape

3 Tiny Stocks to Buy If Biotech Tumbles

Ophthotech Corp., Portola Pharmaceuticals, and Amicus Therapeutics could be buys if biotech stocks fall.

Ophthotech (OPHT) is Overbought: Is A Drop Coming? - Tale of the Tape

5 Drugs That Investors May Be Undervaluing

One Foolish investor thinks these five drugs could send shares in these companies higher.

Cowen & Company Initiates Ophthotech With Outperform

Pop! 3 To Buy If Biotech Stocks Burst

Biotech stocks are falling slightly from their lofty levels, and that may create some interesting opportunities to buy.

Commit To Buy Ophthotech Corp At $40, Earn 8.1% Annualized Using Options

Ophthotech's (OPHT) CEO David Guyer on Q1 2015 Results - Earnings Call Transcript

See More OPHT News...